Edward H Giannini

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. pmc Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology
    Norman T Ilowite
    Children s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA
    Pediatr Rheumatol Online J 10:31. 2012
  2. doi request reprint Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis
    Edward H Giannini
    Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 62:3259-64. 2010
  3. ncbi request reprint Summary of the proceedings of the Institute of Medicine workshop, challenges facing the clinical research enterprise: the response of medical specialty and clinical research societies. How the American College of Rheumatology is addressing areas of concer
    Edward H Giannini
    CCHMC ML 4010, Cincinnati, OH 45229, USA
    Arthritis Rheum 50:3772-5. 2004
  4. doi request reprint A validated disease severity scoring system for Fabry disease
    Edward H Giannini
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45220, USA
    Mol Genet Metab 99:283-90. 2010
  5. ncbi request reprint Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 54:1987-94. 2006
  6. pmc Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Care Res (Hoboken) 62:950-9. 2010
  7. pmc Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, Ohio, USA
    Arthritis Care Res (Hoboken) 63:1213-23. 2011
  8. doi request reprint Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 58:1496-504. 2008
  9. ncbi request reprint Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Rheum 48:218-26. 2003
  10. pmc Toward the development of criteria for global flares in juvenile systemic lupus erythematosus
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Care Res (Hoboken) 62:811-20. 2010

Detail Information

Publications32

  1. pmc Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology
    Norman T Ilowite
    Children s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA
    Pediatr Rheumatol Online J 10:31. 2012
    ..abstract:..
  2. doi request reprint Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis
    Edward H Giannini
    Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 62:3259-64. 2010
    ..To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA)...
  3. ncbi request reprint Summary of the proceedings of the Institute of Medicine workshop, challenges facing the clinical research enterprise: the response of medical specialty and clinical research societies. How the American College of Rheumatology is addressing areas of concer
    Edward H Giannini
    CCHMC ML 4010, Cincinnati, OH 45229, USA
    Arthritis Rheum 50:3772-5. 2004
  4. doi request reprint A validated disease severity scoring system for Fabry disease
    Edward H Giannini
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45220, USA
    Mol Genet Metab 99:283-90. 2010
    ..Our results demonstrate that the Fabry DS3 correlates highly with the clinical assessment by Fabry disease experts...
  5. ncbi request reprint Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 54:1987-94. 2006
    ..The goal of our study was to provide data on safety and efficacy after 4 years of etanercept treatment in patients with JRA...
  6. pmc Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Care Res (Hoboken) 62:950-9. 2010
    ..To determine the minimal clinically important differences (MCIDs) of validated measures of systemic lupus erythematosus (SLE) disease activity in childhood-onset SLE...
  7. pmc Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, Ohio, USA
    Arthritis Care Res (Hoboken) 63:1213-23. 2011
    ..To develop widely acceptable preliminary criteria of global flare for childhood-onset systemic lupus erythematosus (cSLE)...
  8. doi request reprint Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 58:1496-504. 2008
    ..To evaluate the safety and efficacy of up to 8 years of etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA)...
  9. ncbi request reprint Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Rheum 48:218-26. 2003
    ..All patients had been participants in an initial randomized efficacy and safety trial of etanercept...
  10. pmc Toward the development of criteria for global flares in juvenile systemic lupus erythematosus
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Care Res (Hoboken) 62:811-20. 2010
    ..To develop a definition of global flare in juvenile systemic lupus erythematosus (SLE) and derive candidate criteria for measuring juvenile SLE flares...
  11. ncbi request reprint A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage
    Susan D Thompson
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Arthritis Rheum 50:2920-30. 2004
    ..A genome scan was performed to detect linkage to JRA in 121 families containing 247 affected children in North America (the JRA Affected Sibpair [ASP] Registry)...
  12. pmc Inactive disease and remission in childhood-onset systemic lupus erythematosus
    Rina Mina
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, William S Rowe Division of Rheumatology, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
    Arthritis Care Res (Hoboken) 64:683-93. 2012
    ..To define inactive disease (ID) and clinical remission (CR) and to delineate variables that can be used to measure ID/CR in childhood-onset systemic lupus erythematosus (cSLE)...
  13. pmc Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, William Rowe Division of Rheumatology, E 4010, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
    Arthritis Care Res (Hoboken) 62:335-44. 2010
    ..To prospectively validate the provisional criteria for the evaluation of response to therapy in children with systemic lupus erythematosus (SLE)...
  14. doi request reprint Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Division of Rheumatology, Location E, Rm 2 129, MLC 4010, 3333 Burnet Ave, Cincinnati, OH 45229 3039, USA
    N Engl J Med 359:810-20. 2008
    ..We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis...
  15. ncbi request reprint Preliminary definition of disease flare in juvenile rheumatoid arthritis
    Hermine I Brunner
    William S Rowe Division of Rheumatology, Cincinnati Children s Hospital Medical Center, OH 45229, USA
    J Rheumatol 29:1058-64. 2002
    ..To develop preliminary criteria for defining disease flare in patients with polyarticular-course juvenile rheumatoid arthritis (JRA)...
  16. ncbi request reprint Juvenile rheumatoid arthritis affected sibpairs: extent of clinical phenotype concordance
    Marta B Moroldo
    Cincinnati Children s Hospital Medical Center, and University of Cincinnati, Ohio 45229 3039, USA
    Arthritis Rheum 50:1928-34. 2004
    ....
  17. ncbi request reprint Minimal clinically important differences of the childhood health assessment questionnaire
    Hermine I Brunner
    Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    J Rheumatol 32:150-61. 2005
    ..125. We estimated minimal clinically important differences (MCID) of the CHAQ for worsening and improvement that were actually experienced by children with JRA using patient, parent, and clinical perspectives...
  18. ncbi request reprint Health-related quality of life in children with rheumatic diseases
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, OH 45229 3039, USA
    Curr Opin Rheumatol 15:602-12. 2003
    ..For the interpretation of the values of the physical function and health-related quality of life measures, their measurement properties have to be studied...
  19. pmc Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial
    Ruy Carrasco
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Arthritis Rheum 58:3932-40. 2008
    ....
  20. pmc Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Care Res (Hoboken) 63:10-6. 2011
    ..The objective of this effort was to establish a set of QMs for the assessment of the process of care in juvenile idiopathic arthritis (JIA)...
  21. pmc Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome
    Joyce Villanueva
    1Division of Hematology Oncology, Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Arthritis Res Ther 7:R30-7. 2005
    ..This phenomenon was particularly common in the systemic form of JRA, a clinical entity strongly associated with MAS...
  22. ncbi request reprint DNA microarray analysis reveals novel gene expression profiles in collagen-induced arthritis
    Sherry Thornton
    William S Rowe Division of Rheumatology, Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Clin Immunol 105:155-68. 2002
    ..These results demonstrate that global gene expression profiles distinguish early and late CIA and reveal several genes novel to arthritis the further characterization of which will advance our understanding of arthritis...
  23. doi request reprint Advances from clinical trials in juvenile idiopathic arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, ML 4010, Cincinnati, OH 45229, USA
    Nat Rev Rheumatol 9:557-63. 2013
    ....
  24. ncbi request reprint Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis
    Sampath Prahalad
    Department of Pediatrics, University of Utah School of Medicine, Salt Lake City 84132, USA
    Arthritis Rheum 46:1851-6. 2002
    ..To determine if the prevalence of autoimmunity among relatives of patients with juvenile rheumatoid arthritis (JRA) is greater than that among relatives of healthy volunteer control subjects...
  25. doi request reprint Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial
    Nicolino Ruperto
    IRCCS G Gaslini, PRINTO, Genoa, Italy
    Lancet 372:383-91. 2008
    ..We aimed to assess the safety and efficacy of abatacept, a selective T-cell costimulation modulator, in children with juvenile idiopathic arthritis who had failed previous treatments...
  26. ncbi request reprint Methotrexate: vital new information about a middle aged drug
    Edward H Giannini
    J Rheumatol 29:2031-3. 2002
  27. ncbi request reprint Patterns of clinical remission in select categories of juvenile idiopathic arthritis
    Carol A Wallace
    Children s Hospital and Regional Medical Center, and University of Washington School of Medicine, 4800 Sand Point Way NE, Seattle, WA 98105, USA
    Arthritis Rheum 52:3554-62. 2005
    ....
  28. ncbi request reprint A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis
    Nicolino Ruperto
    IRCCS, Istituto G Gaslini, Genoa, Italy
    Arthritis Rheum 56:3096-106. 2007
    ..To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA)...
  29. ncbi request reprint The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement
    Nicolino Ruperto
    Pediatric Rheumatology International Trials Organization, IRCCS G Gaslini, Università di Genova Pediatria II Reumatologia, 5 Largo Gaslini, 16147 Genoa, Italy
    Arthritis Rheum 55:355-63. 2006
    ....
  30. ncbi request reprint Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension
    Andreas Reiff
    Children s Hospital Los Angeles, Los Angeles, CA, USA
    J Rheumatol 33:985-95. 2006
    ..To compare the safety and efficacy of rofecoxib* to naproxen for the treatment of juvenile rheumatoid arthritis (JRA)...
  31. doi request reprint Performing trials in children with rheumatic diseases: comment on the editorial by Lehman
    Nicolino Ruperto
    Arthritis Rheum 58:1201-2; author reply 1203. 2008
  32. ncbi request reprint Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis
    Carol A Wallace
    Division of Immunology, Rheumatology, and Infectious Disease, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    J Rheumatol 33:789-95. 2006
    ..To begin the validation process of the preliminary criteria for inactive disease (ID), clinical remission on medication (CRM), and clinical remission off medication (CR) in children with select forms of juvenile idiopathic arthritis (JIA)...